CTRI/2021/06/034297
Recruiting
未知
A clinical study to evaluate the safety, tolerability and effectiveness of Soreze gel in existing Grade 1 pressure ulcers.
Amaterasu Lifesciences0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Health Condition 1: L899- Pressure ulcer of unspecified site
- Sponsor
- Amaterasu Lifesciences
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •18 YEARS AND ABOVE POPULATIO
Exclusion Criteria
- •The length of stay counting from first day of admission
- •in one or (if the patient is transferred to another ward)
- •more participating wards.
- •Were terminally ill or receiving chemotherapy
- •Presence of diabetes both Type I and II
- •Were allergic to the components of a study product
- •Had peripheral vascular disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
A study to evaluate ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Japanese adults with chronic Hepatitis C Virus infectioJPRN-jRCT2080221883AbbVie GK96
Completed
Not Applicable
A clinical study to evaluate the safety, tolerability, and pharmacokinetics of the MMP 12 inhibitor FP- 025 after multiple oral ascending dose administration, and to evaluate the effect of food after a single oral dose administration in healthy subjectsNL-OMON44633Foresee Pharmaceuticals Co., Ltd.32
Completed
Not Applicable
A clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of LEO 153339 in healthy subjectsPsoriasisNL-OMON51974eo Pharma A/S134
Not yet recruiting
Phase 1
A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adultsovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003169anjing University
Completed
Phase 2
Clinical study to investigate safety, tolerability, efficacy,pharmacokinetics and pharmacodynamics of inhaled multiple doses of the human GATA-3-specific DNAzyme solution SB010 in patients with moderate to severe COPD– A randomised, double-blind, parallel group, multicenter, phase IIa pilot study –J44.9Chronic obstructive pulmonary disease, unspecifiedDRKS00006087Philipps-Universität Marburg19